Melanoma Model

Model Introduction

Melanoma is a malignant tumor originating from neural crest melanocytes, characterized by high morbidity and mortality. In immuno-oncology research, the Syngeneic Graft Model is one of the most widely used tools. The B16 melanoma mouse model is constructed by inoculating mouse-derived B16 melanoma cells into C57BL/6 mice with the same genetic background. The core advantage of this model is that the experimental animals have a complete immune system, which can realistically simulate the inherent interaction between melanocytes and immune cells. This makes it an ideal choice for studying the tumor immune microenvironment and evaluating immunotherapy strategies and anti-tumor drug efficacy.

Research Applications

1. Tumor Immune Microenvironment Research: Exploring the interaction mechanisms between melanocytes and the host immune system.
2. Immunotherapy Drug Evaluation: Used to evaluate the preclinical efficacy of immune checkpoint inhibitors, tumor vaccines, and other immunomodulatory drugs.
3. Tumor Metastasis Mechanism Research: Simulating the orthotopic development and distant metastasis process of melanoma.
4. Preventive Research: Studying preventive measures for tumor formation in conjunction with inducing factors.

Key Points of Experimental Design

1. Animal Species: Inbred mice with a genetic background identical to the tumor cell line are selected, most commonly C57BL/6 mice.
2. Cell Line Selection: Use of the murine B16 melanoma cell line.
3. Modeling Methods:
   • Syngeneic Transplantation: B16 melanoma cells cultured to the logarithmic growth phase are inoculated subcutaneously or into specific sites in C57BL/6 mice.
   • Induced Assistance (Optional): In specific studies, ultraviolet (UV) irradiation or application of chemical carcinogens (e.g., DMBA, TPA) may be combined to simulate immune responses and skin lesions induced by external factors.
4. Critical Steps:
   • Ensure the viability and concentration of the inoculated cells.
   • Maintain the mice in an immunocompetent state throughout the experiment to ensure the comprehensiveness of immune system functions.

Key Monitoring Indicators

1. Tumor Growth Kinetics: Monitoring the time of primary tumor appearance (latency period) and its growth rate.
2. Immune Cell Infiltration: Observing the distribution of immune cells within the tumor tissue and their interaction with melanocytes.
3. Metastasis Status: Assessing invasive metastatic lesions in lymph nodes and distant organs.
4. Histopathological Characteristics: Observing dermal components, vertical growth phase characteristics, and pigment cell accumulation patterns via tissue sectioning.
5. Survival Monitoring: Recording the impact of tumor burden on the survival rate of the mice.